SCANCELL

 

SCANCELL (SCLP.L, LSE, LSE:SCLP)

SCLP Share PerformanceMore

52 week high40.490 30/10/14
52 week low22.435 02/04/15
52 week change -4.750 (-14.29%)
4 week volume8,723,228 24/03/15

Media for (SCLP)

Presenter: Mike Mitchell, Director, Equity Research
11/12/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Poster on Moditope to be presented at AACR

RNS Number: 4991K Scancell Holdings Plc 17 April 2015 17 April 2015 Scancell Holdings Plc Moditope citrullinated peptides destroy tumours and extend survival Poster to be presented at American Association for Cancer Research Annual Meeting Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, to...

Second Price Monitoring Extn

RNS Number: 3540I Scancell Holdings Plc 24 March 2015 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The closing auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determ...

Price Monitoring Extension

RNS Number: 3520I Scancell Holdings Plc 24 March 2015 Price Monitoring Extension Today's closing auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's closing auction call be...

SCIB2 synergy with checkpoint inhibitor blockade

RNS Number: 2476I Scancell Holdings Plc 24 March 2015 24 March 2015 Scancell Holdings Plc SCIB2 also shown to synergise with checkpoint inhibitor blockade Combining SCIB2 with CTLA-4 blockade enhances tumour destruction and extends survival times Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatme...

Scancell Holdings - SCIB2 also shown to synergise with checkpoint inhibitor blockade

Positive SCIB1 Phase 1/2 clinical trial update

RNS Number: 8434B Scancell Holdings Plc 12 January 2015 12 January 2015 Scancell Holdings Plc Scancell to provide positive SCIB1 Phase 1/2 clinical trial update during corporate presentations 12-15 January, San Francisco Part 2 patients have median survival time of 28 months since study entry All resected patients are still alive with median survival time of 30 mont...

Holding(s) in Company

RNS Number: 8294Z Scancell Holdings Plc 15 December 2014 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Scancell Holdings plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An...

Scancell Holdings - Analyst Interview, Panmure Gordon